Maze Therapeutics, Inc. (MAZE) Cash Flow Statement
Maze Therapeutics, Inc. (MAZE) generated -$106.5M of operating cash flow over the twelve months to 2026-06-30, spent $302000 on capital expenditure and had free cash flow of -$106.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MAZEMaze Therapeutics, Inc.Follow MAZE — free
—
Price chart with a free account
- Market cap
- 1.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | 76.0 | -111.9 | -106.5 | |
| Capital expenditure | 1.1 | 0.8 | -0.3 | |
| Free cash flow | 74.8 | -112.7 | -106.8 | |
| Dividends paid | — | 0.0 | — | |
| Stock-based compensation | 9.6 | 16.4 | — |
USD millions · SEC XBRL
Maze Therapeutics, Inc. — questions
- What is Maze Therapeutics, Inc.'s operating cash flow?
- -$106.5M over the twelve months to 2026-06-30.
- How much does Maze Therapeutics, Inc. spend on capital expenditure?
- $302000 over the twelve months to 2026-06-30.
- What is Maze Therapeutics, Inc.'s free cash flow?
- -$106.8M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Maze Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.